Investigación e Informes
24 sept 2026•1 min de lectura
AbbVie reports positive Phase 3 results for Qulipta in menstrual migraine
AbbVie’s Qulipta (atogepant) reduced migraine days versus placebo in a Phase 3 menstrual migraine study, meeting the primary endpoint and supporting label expansion.
Investigación e Informes
23 ago 2026•1 min de lectura
PMDA Concludes MoU with London School of Hygiene & Tropical Medicine
The Pharmaceuticals and Medical Devices Agency (PMDA) has signed a Memorandum of Understanding with the London School of Hygiene & Tropical Medicine to promote joint work in pharmaceutical research and regulatory science.
Investigación e Informes
23 ago 2026•1 min de lectura
PMDA Updates One-Stop Service Platform by ENSEMBLExJ
The Pharmaceuticals and Medical Devices Agency (PMDA) has refreshed the One-Stop Service Platform page for ENSEMBLExJ, providing updated information for stakeholders.